文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌复发SABR再照射的多中心回顾性研究

A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence.
PubMed 文献 · Radiother Oncol · 2021-06-25

本研究回顾性分析3家英国中心2015年8月至2020年9月间因局部复发直肠癌接受SABR再照射的69例患者(81个病灶),方案为30 Gy/5次。中位随访28个月,中位无进展生存期12.1个月,中位总生存期38.7个月,2年总生存率0.77。结论认为该结果对不适合或拒绝手术及R1切除后患者令人鼓舞,但需前瞻性数据确立SABR作为手术替代的地位。

要点

  • 局部复发直肠癌SABR再照射30 Gy/5次,中位总生存期38.7个月,2年总生存率0.77。
  • 58.3%的死亡归因于局部复发后果,42.6%的患者在死亡或末次随访时出现局部复发。
  • 该结果与手术系列相似,支持在拒绝或不适合手术者中开展前瞻性研究。

核心结论

  • 对R1切除后、拒绝或被拒绝手术的局部复发直肠癌患者,SABR再照射的生存结局与手术系列相似,令人鼓舞。
  • 需纳入生存、局部复发和生活质量细节的前瞻性数据及优化SABR技术,才能确立SABR作为手术替代方案。

研究设计与样本

  • 多中心回顾性分析,纳入3家英国中心2015年8月至2020年9月接受SABR再照射的局部复发直肠癌患者。
  • eligible患者为盆腔复发且不适合或选择不做手术,或扩大切除术后切缘阳性;治疗方案为30 Gy分5次。
  • 共识别69例患者、81个病灶,中位随访28个月,随访含临床评估和CT扫描(3、6、12、18、24个月)。

主要发现

  • 中位无进展生存期为12.1个月(10.4,17.7),中位总生存期为38.7个月(28.9,-)。
  • 2年总生存率为0.77(0.66,0.89)。
  • 58.3%的死亡由局部复发后果导致。
  • 42.6%的患者在死亡或末次随访时存在局部复发。

临床怎么用

  • 对于局部复发直肠癌中不适合手术、拒绝手术或R1切除后的患者,可考虑SABR再照射30 Gy/5次作为一种非手术治疗选择。
  • 治疗前应充分评估盆腔复发范围及既往放疗史,并按3、6、12、18、24个月进行临床和CT随访。

局限性

  • 为回顾性多中心设计,样本量有限(69例患者、81个病灶)。
  • 缺乏生活质量数据,且无前瞻性对照验证。
  • 原文未报告SABR再照射的具体技术细节和既往放疗剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Locally recurrent rectal cancer (LRRC) is associated with considerable morbidity, poor quality of life and an overall survival of 9 months. The non-operative treatment of LRRC is an understudied area, there is no consensus on management in this setting. We aim to perform a retrospective, multicentre analysis of patients treated with SABR reirradiation. MATERIALS AND METHODS: All patients were identified who received SABR re-irradiation for LRRC, at 3 UK centres, between August 2015 and September 2020. Eligible patients had pelvic recurrence and were either not suitable/opted not for surgery, or margin positive after exenturative surgery. Patients were treated with 30 Gy in 5 fractions and followed up with clinical review and CT scan at 3, 6, 12, 18 and 24 months. RESULTS: 69 patients with 81 lesions were identified and median follow up was 28 months. Median progression free survival (PFS) and overall survival (OS) were 12.1 months (10.4, 17.7) and 38.7 months (28.9,-) respectively. 2-year OS was 0.77 (0.66, 0.89). 58.3% of deaths were as a result of consequences of local relapse. 42.6% of patients had local relapse at death or last follow up. CONCLUSION: Our outcomes are encouraging for a population who had R1 resections, refused or were refused surgery; as they are similar to those in surgical series. Prospective data including details of survival, local relapse and QOL; with an optimised SABR technique, is required to establish SABR as an alternative to surgery.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Johnstone P, Okonta L, Aitken K, et al. A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence. Radiother Oncol. 2021. PMID: 34182013. doi:10.1016/j.radonc.2021.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。